Cytokinetics Inc CYTK:NASDAQ

Robert I Blum, Director, President & CEO, on May 16, 2022, sold 10,000 shares in Cytokinetics (CYTK) for $431,065. Following the Form 4 filing with the SEC, Blum has control over a total of 413,290 shares of the company, with 409,124 shares held directly and 4,166 controlled indirectly. The market value of the direct and indirect holding, based on the transaction price, is approximately $17,815,485.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1061983/000106198322000127/xslF345X03/edgardoc.xml

Price: 40.12, Change: +1.47, Percent Change: +3.8